- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07585552
Anesthesia Type and HoLEP Outcomes: A Multi-Center Study
Does Anesthesia Type Affect HoLEP Outcomes? A Multi-Center, Real-World Comparative Study
What is this study about, and why is it required?
The goal of this observational study is to learn if anesthesia type (e.g., general anesthesia, spinal anesthesia) affects the safety and efficiency of HoLEP surgery. The main question it aims to answer is:
- Is a particular type of anesthesia related to less or more bleeding during the surgery?
What will be assessed to answer the main question of this study? (Outcome measure(s))
2.1. Primary outcome measure of this study is:
- Change in the hemoglobin level perioperatively.
2.2. Secondary outcome measures are:
- Requirement for the usage of any vasoactive medication due to low blood pressure
- Time passed until discharge.
- Time passed until the removal of the bladder drainage catheter.
- Ratio of the unwanted events that require additional intervention other than medication, fluids, or blood transfusions (Complications, Clavien-Dindo Grade III or higher).
- International symptom questionnaire score 3 months after surgery.
- Quality of life (QoL) score 3 months after surgery.
- Peak urinary current velocity (Qmax) and post-void residual volume measurement 3 months after surgery.
- Can anyone participate in this study?
Voluntary participants should meet the following criteria:
- Being older than 18 years old.
- Having bothersome lower urinary tract symptoms due to prostatic enlargement requiring surgical treatment.
- Having no untreated or uncontrolled systemic disease, which refers to having an ASA (American Society of Anesthesiologists Physical Status Classification System) score III at most.
Study Overview
Status
Detailed Description
Benign prostatic obstruction (BPO) is the leading cause of lower urinary tract symptoms (LUTS) among men older than 40 years.
Surgery is recommended under circumstances such as:
- Bothersome LUTS resistant to medical treatment.
- Acute kidney injury, bladder stone(s), resistant hematuria and urinary retention.
- Preference of the patient.
Various surgical methods exist to treat BPO, but the most appropriate choice depends on the operator and the patient.
HoLEP is an abbreviation for holmium laser enucleation of prostate, which is one of the endoscopic laser enucleation techniques.
Both spinal and general anesthesia are applicable for HoLEP surgery. The type of anesthesia is determined by the anesthesiologist, independently of the operator's preference, taking into account several factors related to the patient, such as safety and comfort.
Controlled bleeding is one of the expected outcomes in HoLEP, and several factors determine the amount of bleeding. For HoLEP, the type of anesthesia may be one of them, as other studies have claimed. This multicenter, prospective observational study may further reveal the impact of anesthesia type on bleeding.
The amount of bleeding could be "less or more", determined according to the content below:
- Amount of hemoglobin and hematocrit decreased, measured by laboratory examinations, preoperatively, during, and on the day after the surgery.
- Vital changes such as hypotension, tachycardia, that require blood transfusion due to "more" bleeding during either the surgery or hospital stay after surgery.
- Usually, a shorter duration of bladder irrigation to clean blood in the urine during hospital stay after the surgery is required for "less" bleeding.
Participants who are eligible and willing to provide informed consent will undergo HoLEP. Preoperative, perioperative, and postoperative data will be collected without disclosing the participant or any personal data relating to the participant.
Participants will be grouped into two groups based on anesthesia type: general or spinal.
To answer the main question of this study, a power analysis was conducted, concluding that at least 320 participants are required (intention-to-treat population).
All collected data will be recorded and analyzed according to the proper statistical methods. Results will be reported.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Murat Gulsen, Assistant Professor
- Phone Number: +905062357421
- Email: mglotr@gmail.com
Study Locations
-
-
-
Samsun, Turkey (Türkiye)
- Ondokuz Mayis University, Faculty of Medicine, Department of Urology
-
Contact:
- Murat Gulsen, Assistant Professor
- Phone Number: +905062357421
- Email: mglotr@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- 18 years or older men who have BPO requiring surgical treatment.
- Participants who can give written informed consent.
- Having no more than 3 points for the American Society of Anesthesiologists (ASA) physical status classification scale (ASA 1 to 3).
Exclusion Criteria:
- Absolute contraindication for spinal or general anesthesia
- History of previous surgery for prostate (e.g., surgery for prostate cancer, surgery for benign prostate obstruction)
- Uncorrected bleeding disorder (INR > 1.5)
- Participants who are not willing to give informed consent.
- Participants who have a proven urinary tract infection at the time of the surgery.
- Participants who are not able to be contacted for regular follow-ups.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
General Anesthesia
Participants undergoing HoLEP under general anesthesia (intubation or laryngeal mask airway)
|
|
Spinal Anesthesia
Participants undergoing HoLEP under spinal anesthesia
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Hemoglobin change
Time Frame: First day after HoLEP is performed.
|
Difference between preoperative and postoperative hemoglobin levels (g/dL)
|
First day after HoLEP is performed.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
International Prostate Symptom with quality of life score (IPSS-QoL) at 3 months after surgery
Time Frame: At 3 months after HoLEP
|
The severity of lower urinary tract symptoms and their impact on quality of life should be assessed using a validated questionnaire.
|
At 3 months after HoLEP
|
|
Duration of hospitalization
Time Frame: Postoperative second to seventh days after HoLEP.
|
Day(s) passed until discharge after HoLEP.
|
Postoperative second to seventh days after HoLEP.
|
|
Duration of catheterization
Time Frame: From the time of HoLEP until the removal of the catheter.
|
Day(s) passed until the removal of the bladder drainage catheter after HoLEP.
|
From the time of HoLEP until the removal of the catheter.
|
|
Ratio of high grade complications
Time Frame: From the time of HoLEP to 30 days after HoLEP.
|
Complications will be classified according to the Clavien-Dindo classification.
Clavien-Dindo Grade III or higher is considered a high-grade complication.
|
From the time of HoLEP to 30 days after HoLEP.
|
|
Peak Urinary Flow (Qmax)
Time Frame: At 3 months after HoLEP.
|
Peak urinary flow (mL/sec), at 3 months after HoLEP.
|
At 3 months after HoLEP.
|
|
Post-void residual (PVR)
Time Frame: At 3 months after HoLEP
|
Post-void residual (PVR) volume (mL) measurement at 3 months after HoLEP
|
At 3 months after HoLEP
|
|
Enucleation Efficiency
Time Frame: From the start of HoLEP to the end of HoLEP (Operative time).
|
Weight of the enucleated adenoma per operative minute (grams/min).
|
From the start of HoLEP to the end of HoLEP (Operative time).
|
|
Ratio of intraoperative vasoactive medication requirement
Time Frame: During the anesthesia for HoLEP
|
Number of participants who required vasoactive medication during anesthesia for HoLEP due to low blood pressure, as a percentage of the total number of participants.
|
During the anesthesia for HoLEP
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Murat Gulsen, Ondokuz Mayıs University
Publications and helpful links
General Publications
- Haehn DA, Chadha RM, Porter SB, Pathak RA, Lyon TD, Hochwald AP, Dora CD. Same-day Discharge Following Holmium Laser Enucleation of the Prostate Under Spinal Anesthesia: A Propensity Score Matched Comparison With General Anesthesia. Urology. 2025 Feb;196:260-264. doi: 10.1016/j.urology.2024.11.058. Epub 2024 Nov 30.
- Silvani C, Lucignani G, Bebi C, Turetti M, Ripa F, Zanetti SP, De Lorenzis E, Albo G, Longo F, Gadda F, Montanari E, Boeri L. General anesthesia is associated with lower perioperative bleeding and better functional outcomes than spinal anesthesia for endoscopic enucleation of the prostate: a single-center experience. World J Urol. 2024 Oct 9;42(1):569. doi: 10.1007/s00345-024-05271-z.
- Westhofen T, Schott M, Keller P, Tamalunas A, Atzler M, Ebner B, Schultheiss M, Damm A, Kowalski C, Stief CG, Magistro G. Spinal Versus General Anesthesia for Holmium Laser Enucleation of the Prostate of High-risk Patients - A Propensity-score-matched-analysis. Urology. 2022 Jan;159:182-190. doi: 10.1016/j.urology.2021.04.078. Epub 2021 Jul 31.
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- MIUS.2026.002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Individual participant data (IPD) will not be shared due to privacy concerns and data protection regulations, including the Turkish Personal Data Protection Law (KVKK).
Only aggregated, de-identified results will be reported in publications and presentations.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Benign Prostatic Hyperplasia With Symptomatic Lower Urinary Tract Symptoms
-
South Valley UniversityRecruitingBenign Prostatic Hyperplasia With Lower Urinary Tract Symptoms | Benign Prostatic Hyperplasia With Symptomatic Lower Urinary Tract Symptoms | Benign Prostatic Hyperplasia (BPH) Requiring Surgical Resection | Benign Prostatic Hyperplasia With Outflow ObstructionEgypt
-
Ain Shams UniversityRecruitingBenign Prostatic Hyperplasia With Lower Urinary Tract SymptomsEgypt
-
University of CalgaryNot yet recruitingBenign Prostatic Hyperplasia | Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms | Benign Prostatic Hyperplasia With Outflow ObstructionCanada
-
Shanghai Huilun Pharmaceutical Co., Ltd.Not yet recruitingBenign Prostatic Hyperplasia | Benign Prostatic Hyperplasia With Lower Urinary Tract SymptomsChina
-
Xintian PharmaceuticalRecruitingBenign Prostatic Hyperplasia With Lower Urinary Tract SymptomsChina
-
Dong-A Pharmaceutical Co., Ltd.CompletedLower Urinary Tract Symptoms Associated With Benign Prostatic HyperplasiaKorea, Republic of
-
University of California, San DiegoCompletedProstatic Hyperplasia, Benign | Enlarged Prostate With Lower Urinary Tract SymptomsUnited States
-
Astellas Pharma IncAstellas Pharma Taiwan, Inc.CompletedLower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH)Taiwan
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Not yet recruitingLower Urinary Tract Symptoms | Benign Prostate Hyperplasia | Benign Prostatic Hypertrophy With Outflow Obstruction
-
Ondokuz Mayıs UniversityCukurova University; Gazi University; Marmara University; Dokuz Eylul University; Tepecik Training and Research Hospital and other collaboratorsEnrolling by invitationBenign Prostatic Hyperplasia With Lower Urinary Tract SymptomsTurkey (Türkiye)